Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis.

2.50
Hdl Handle:
http://hdl.handle.net/10147/254794
Title:
Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis.
Authors:
Glackin, L; Leen, G; Elnazir, B; Greally, P
Affiliation:
Department of Respiratory Medicine, National Children's Hospital, Tallaght, Dublin 24. Peter.Greally@amnch.ie
Citation:
Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. 2009, 102 (1):29 Ir Med J
Journal:
Irish medical journal
Issue Date:
Jan-2009
URI:
http://hdl.handle.net/10147/254794
PubMed ID:
19284017
Abstract:
Allergic bronchopulmonary aspergillosis (ABPA) can cause a significant clinical deterioration in patients with cystic fibrosis. There is very little research in the current literature with regard to alternatives for treatment, apart from long courses of steroids. We conducted a retrospective review of all our patients with ABPA treated with the antifungal voriconazole and found there was a significant drop in IgE levels post treatment as well as a decrease in steroid dosing. The improvement in FEV was not statistically significant; however there was a very wide variation in pre-treatment levels.
Item Type:
Article
Language:
en
MeSH:
Adolescent; Antifungal Agents; Aspergillosis, Allergic Bronchopulmonary; Confidence Intervals; Cystic Fibrosis; Female; Forced Expiratory Volume; Humans; Immunoglobulin E; Male; Pyrimidines; Retrospective Studies; Triazoles
ISSN:
0332-3102

Full metadata record

DC FieldValue Language
dc.contributor.authorGlackin, Len_GB
dc.contributor.authorLeen, Gen_GB
dc.contributor.authorElnazir, Ben_GB
dc.contributor.authorGreally, Pen_GB
dc.date.accessioned2012-12-06T15:39:18Z-
dc.date.available2012-12-06T15:39:18Z-
dc.date.issued2009-01-
dc.identifier.citationVoriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. 2009, 102 (1):29 Ir Med Jen_GB
dc.identifier.issn0332-3102-
dc.identifier.pmid19284017-
dc.identifier.urihttp://hdl.handle.net/10147/254794-
dc.description.abstractAllergic bronchopulmonary aspergillosis (ABPA) can cause a significant clinical deterioration in patients with cystic fibrosis. There is very little research in the current literature with regard to alternatives for treatment, apart from long courses of steroids. We conducted a retrospective review of all our patients with ABPA treated with the antifungal voriconazole and found there was a significant drop in IgE levels post treatment as well as a decrease in steroid dosing. The improvement in FEV was not statistically significant; however there was a very wide variation in pre-treatment levels.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Irish medical journalen_GB
dc.subject.meshAdolescent-
dc.subject.meshAntifungal Agents-
dc.subject.meshAspergillosis, Allergic Bronchopulmonary-
dc.subject.meshConfidence Intervals-
dc.subject.meshCystic Fibrosis-
dc.subject.meshFemale-
dc.subject.meshForced Expiratory Volume-
dc.subject.meshHumans-
dc.subject.meshImmunoglobulin E-
dc.subject.meshMale-
dc.subject.meshPyrimidines-
dc.subject.meshRetrospective Studies-
dc.subject.meshTriazoles-
dc.titleVoriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Respiratory Medicine, National Children's Hospital, Tallaght, Dublin 24. Peter.Greally@amnch.ieen_GB
dc.identifier.journalIrish medical journalen_GB
dc.description.provinceLeinsteren

Related articles on PubMed

All Items in Lenus,the Irish health repository are protected by copyright, with all rights reserved, unless otherwise indicated.